Drug Target Review Issue 1 2019
In this issue: AI-driven automated chemistry as a tool to accelerate drug discovery processes, the shifting landscape of immuno-oncology, and how lipid molecules provide an insight into biological research.
Included in this issue:
- CELL LINE DEVELOPMENT
Cell line development – global market drivers, trends and its impact on improving biologics development from early phase to IND during the drug discovery process
Aparajita Dubey, Associate Consultant at Prescient Healthcare Group
The importance of characterising chemical starting points of drugs using appropriate in vitro ADME-toxicity assays
Massimiliano Runfola, University of Pisa and Sheraz Gul,
Kick-starting the immune response – the shifting landscape of immuno-oncology
Nathan Robertson, Oxford Genetics
- LAB AUTOMATION
Drug discovery from the age of informationto the age of intelligence
Jeff Martin, Head of Compound Management, Alkermes, Inc.
Farther than fat: how lipids change research
Dr Christian Klose, Head of Research & Development at Lipotype GmbH
Network-driven drug discovery
Jonny Wray and Alan Whitmore, e-therapeutics plc.
This issue is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!